Differential effects of thioridazine enantiomers on action potential duration in rabbit papillary muscle

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Differential effects of thioridazine enantiomers on action potential duration in rabbit papillary muscle. / Jensen, Ask Schou; Pennisi, Cristian Pablo; Sevcencu, Cristian; Christensen, Jørn Bolstad; Kristiansen, Jette Elisabeth; Struijk, Johannes Jan.

I: European Journal of Pharmacology, Bind 747, 15.01.2015, s. 7-12.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Jensen, AS, Pennisi, CP, Sevcencu, C, Christensen, JB, Kristiansen, JE & Struijk, JJ 2015, 'Differential effects of thioridazine enantiomers on action potential duration in rabbit papillary muscle', European Journal of Pharmacology, bind 747, s. 7-12. https://doi.org/10.1016/j.ejphar.2014.11.015

APA

Jensen, A. S., Pennisi, C. P., Sevcencu, C., Christensen, J. B., Kristiansen, J. E., & Struijk, J. J. (2015). Differential effects of thioridazine enantiomers on action potential duration in rabbit papillary muscle. European Journal of Pharmacology, 747, 7-12. https://doi.org/10.1016/j.ejphar.2014.11.015

Vancouver

Jensen AS, Pennisi CP, Sevcencu C, Christensen JB, Kristiansen JE, Struijk JJ. Differential effects of thioridazine enantiomers on action potential duration in rabbit papillary muscle. European Journal of Pharmacology. 2015 jan. 15;747:7-12. https://doi.org/10.1016/j.ejphar.2014.11.015

Author

Jensen, Ask Schou ; Pennisi, Cristian Pablo ; Sevcencu, Cristian ; Christensen, Jørn Bolstad ; Kristiansen, Jette Elisabeth ; Struijk, Johannes Jan. / Differential effects of thioridazine enantiomers on action potential duration in rabbit papillary muscle. I: European Journal of Pharmacology. 2015 ; Bind 747. s. 7-12.

Bibtex

@article{8f81b68c18f74cb7ae76a831aa715a39,
title = "Differential effects of thioridazine enantiomers on action potential duration in rabbit papillary muscle",
abstract = "The antipsychotic drug thioridazine has potential for treatment of multidrug-resistant microbes including tuberculosis but also causes cardiotoxic QT interval prolongation. Both thioridazine enantiomers have potent antimicrobial effects, but the neuroleptic effect primarily resides with (+)-thioridazine. In this study we for the first time investigate the cardiotoxicity of the isolated thioridazine enantiomers and show their effects on ventricular repolarization. The effects of (+)-thioridazine, (-)-thioridazine, and racemate on the rabbit ventricular action potential duration (APD) were investigated in a randomized controlled blinded experiment. Action potentials were measured in papillary muscles isolated from 21 female rabbits, and the drug effect on 90% APD in comparison with control (ΔΔ-APD90) was evaluated. Increasing concentrations of (+)-thioridazine and the racemate caused significant dose-dependent ΔΔ-APD90 prolongation, while (-)-thioridazine did not. At 0.5 and 2 Hz pacing, (+)-thioridazine caused 19.5% and 20.1% ΔΔ-APD90 prolongation, the racemate caused 8.0% and 12.9%, and (-)-thioridazine caused 1.5% and 1.1%. The effect of (-)-thioridazine on APD90 was significantly less than that of the other drugs at both pacing rates (P<0.01 in all cases), and there was no significant difference between (-)-thioridazine and control. The results of this study indicate that the APD prolonging effect of thioridazine is primarily due to the (+)-thioridazine enantiomer. If these results are valid in humans, (-)-thioridazine may be a safer drug for treatment of multidrug-resistant tuberculosis and other microbes.",
keywords = "APD prolongation, Isolated papillarymuscle, QT prolongation, Reversalofresistance, Thioridazine, Ventricular actionpotential",
author = "Jensen, {Ask Schou} and Pennisi, {Cristian Pablo} and Cristian Sevcencu and Christensen, {J{\o}rn Bolstad} and Kristiansen, {Jette Elisabeth} and Struijk, {Johannes Jan}",
year = "2015",
month = jan,
day = "15",
doi = "10.1016/j.ejphar.2014.11.015",
language = "English",
volume = "747",
pages = "7--12",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Differential effects of thioridazine enantiomers on action potential duration in rabbit papillary muscle

AU - Jensen, Ask Schou

AU - Pennisi, Cristian Pablo

AU - Sevcencu, Cristian

AU - Christensen, Jørn Bolstad

AU - Kristiansen, Jette Elisabeth

AU - Struijk, Johannes Jan

PY - 2015/1/15

Y1 - 2015/1/15

N2 - The antipsychotic drug thioridazine has potential for treatment of multidrug-resistant microbes including tuberculosis but also causes cardiotoxic QT interval prolongation. Both thioridazine enantiomers have potent antimicrobial effects, but the neuroleptic effect primarily resides with (+)-thioridazine. In this study we for the first time investigate the cardiotoxicity of the isolated thioridazine enantiomers and show their effects on ventricular repolarization. The effects of (+)-thioridazine, (-)-thioridazine, and racemate on the rabbit ventricular action potential duration (APD) were investigated in a randomized controlled blinded experiment. Action potentials were measured in papillary muscles isolated from 21 female rabbits, and the drug effect on 90% APD in comparison with control (ΔΔ-APD90) was evaluated. Increasing concentrations of (+)-thioridazine and the racemate caused significant dose-dependent ΔΔ-APD90 prolongation, while (-)-thioridazine did not. At 0.5 and 2 Hz pacing, (+)-thioridazine caused 19.5% and 20.1% ΔΔ-APD90 prolongation, the racemate caused 8.0% and 12.9%, and (-)-thioridazine caused 1.5% and 1.1%. The effect of (-)-thioridazine on APD90 was significantly less than that of the other drugs at both pacing rates (P<0.01 in all cases), and there was no significant difference between (-)-thioridazine and control. The results of this study indicate that the APD prolonging effect of thioridazine is primarily due to the (+)-thioridazine enantiomer. If these results are valid in humans, (-)-thioridazine may be a safer drug for treatment of multidrug-resistant tuberculosis and other microbes.

AB - The antipsychotic drug thioridazine has potential for treatment of multidrug-resistant microbes including tuberculosis but also causes cardiotoxic QT interval prolongation. Both thioridazine enantiomers have potent antimicrobial effects, but the neuroleptic effect primarily resides with (+)-thioridazine. In this study we for the first time investigate the cardiotoxicity of the isolated thioridazine enantiomers and show their effects on ventricular repolarization. The effects of (+)-thioridazine, (-)-thioridazine, and racemate on the rabbit ventricular action potential duration (APD) were investigated in a randomized controlled blinded experiment. Action potentials were measured in papillary muscles isolated from 21 female rabbits, and the drug effect on 90% APD in comparison with control (ΔΔ-APD90) was evaluated. Increasing concentrations of (+)-thioridazine and the racemate caused significant dose-dependent ΔΔ-APD90 prolongation, while (-)-thioridazine did not. At 0.5 and 2 Hz pacing, (+)-thioridazine caused 19.5% and 20.1% ΔΔ-APD90 prolongation, the racemate caused 8.0% and 12.9%, and (-)-thioridazine caused 1.5% and 1.1%. The effect of (-)-thioridazine on APD90 was significantly less than that of the other drugs at both pacing rates (P<0.01 in all cases), and there was no significant difference between (-)-thioridazine and control. The results of this study indicate that the APD prolonging effect of thioridazine is primarily due to the (+)-thioridazine enantiomer. If these results are valid in humans, (-)-thioridazine may be a safer drug for treatment of multidrug-resistant tuberculosis and other microbes.

KW - APD prolongation

KW - Isolated papillarymuscle

KW - QT prolongation

KW - Reversalofresistance

KW - Thioridazine

KW - Ventricular actionpotential

U2 - 10.1016/j.ejphar.2014.11.015

DO - 10.1016/j.ejphar.2014.11.015

M3 - Journal article

C2 - 25449032

AN - SCOPUS:84916898704

VL - 747

SP - 7

EP - 12

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -

ID: 261046592